Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Pacific Edge Limited
PFGTFPacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect, which enables the risk stratification of patients with haematuria; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence. In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand. Address: Centre for Innovation, Dunedin, New Zealand, 9016
Analytics
Precio Objetivo de WallStreet
–Relación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave PFGTF
Análisis de dividendos PFGTF
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout PFGTF
Valoración de la acción PFGTF
Finanzas PFGTF
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |